Citation: D. Jung et al., STEADY-STATE RELATIVE BIOAVAILABILITY OF 3 ORAL GANCICLOVIR DOSAGE REGIMENS DELIVERING 6,000 MG DAY IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS/, Journal of clinical pharmacology, 38(11), 1998, pp. 1021-1024
Authors:
JUNG D
GRIFFY K
DORR A
RASCHKE R
TARNOWSKI TL
HULSE J
KATES RE
Citation: D. Jung et al., EFFECT OF HIGH-DOSE ORAL GANCICLOVIR ON DIDANOSINE DISPOSITION IN HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)-POSITIVE PATIENTS, Journal of clinical pharmacology, 38(11), 1998, pp. 1057-1062
Authors:
PESCOVITZ MD
PRUETT TL
GONWA T
BROOK B
MCGORY R
WICKER K
GRIFFY K
ROBINSON CA
JUNG D
Citation: Md. Pescovitz et al., ORAL GANCICLOVIR DOSING IN TRANSPLANT RECIPIENTS AND DIALYSIS PATIENTS BASED ON RENAL-FUNCTION, Transplantation, 66(8), 1998, pp. 1104-1107
Authors:
WOLFE EJ
MATHUR V
TOMLANOVICH S
JUNG D
WONG R
GRIFFY K
AWEEKA FT
Citation: Ej. Wolfe et al., PHARMACOKINETICS OF MYCOPHENOLATE MOFETIL AND INTRAVENOUS GANCICLOVIRALONE AND IN COMBINATION IN RENAL-TRANSPLANT RECIPIENTS, Pharmacotherapy, 17(3), 1997, pp. 591-598